Kornimate/medical-research-clean huggingface dataset:
short integrative and neurocognitive therapy for young adults with borderline personality disorder

Conditions: Borderline Personality Disorder

Summary: borderline personality disorder (bpd) is a severe, high-suicidal psychiatric disorder associated with impulsive, endangering behaviors. young patients between 16 and 25 years old do not respond to traditional psychotherapies, which are often long and not adapted to their neurocognitive alterations linked to early trauma. the study authors hypothesize the sintya therapy program (one group session and one individual session weekly for 10 weeks) would reduce the level of impulsivity and clinical symptomatology (severity of the bpd; emotional regulation difficulties; dissociative symptoms; aggressiveness; ruminations; the number of self-destructive behaviors and suicidal acts; impulsive behaviors; level of suicide risk and hopelessness; the number of psychiatric hospitalizations and emergency visits for psychiatric reasons; and finally improving psychosocial functioning).


Eligibility criteria:
inclusion criteria: * diagnosis of bpd according to dsm-5 criteria and bpq-80 scale. * high bpd severity level: zan-bpd (score ≥ 18/36). * understand, write and read french. * be able to understand the nature, purpose and methodology of the study and agree to cooperate during evaluations. * have signed the informed consent. * for minor patients, have signed the parental consent by at least one holder of parental authority. exclusion criteria: * refusal to participate. * existence of a neurological pathology or cerebral sequelae of organic origin which could affect neurocognitive performance. * intelligence quotient \< 70. * lifetime diagnosis of schizoaffective disorder or schizophrenia (mini-7). * previous or current participation in specific psychotherapy for bpd. * subject deprived of liberty (by judicial or administrative decision) and/or protected by law. * inclusion in another study including psychotherapy for the duration of the study. * inclusion in a drug riph1 study or in a rec study (european regulation of clinical trials) for the entire duration of the study. * subject in period of exclusion from another research protocol.
a prospective study: smart phone application for measure serum bilirubin through sclera images

Conditions: Jaundice; Deep Learning; Hyperbilirubinemia; Sclera

Summary: the primary efficacy endpoints are the standard deviation and coefficient of determination (r2) between predicted and actual values for the bilirubin regression model, and the grading accuracy for the jaundice severity classification model. the secondary efficacy endpoint is the mean percentage error between predicted and actual bilirubin values. there are no relevant safety risks. statistical differences for categorical variables (e.g., jaundice grading evaluation indicators) will be analyzed using the chi-square test or fisher's exact probability test. for continuous variables (e.g., bilirubin prediction evaluation indicators), t-tests (normal distribution) or non-parametric tests (non-normal distribution) will be used. the 95% confidence interval for jaundice grading accuracy will be calculated using the wilson method. the study duration is estimated to be 3 months.


Eligibility criteria:
inclusion criteria: age 14 years or older. subjects who are visiting the gastroenterology department of xijing hospital and will undergo liver function tests on the same day. the disease spectrum of the subjects mainly includes pancreatitis, pancreatic tumors, hepatobiliary stones, biliary tumors, and colonic polyps. exclusion criteria: subjects with diseases that may cause abnormal changes in scleral color, such as glaucoma, wilson's disease, pterygium, or scleritis. subjects who have recently consumed a large amount of carotenoid-rich foods (such as oranges or carrots). subjects who are unable to provide informed consent. elimination criteria: subjects with incomplete scleral exposure due to limited eye movement or excessive tension during external eye examination. subjects who are unable to understand the instructions for eye rotation during scleral examination or are unable to cooperate due to reasons such as poor hearing.

Keywords: smart phone hyperbilirubinemia real-time deep learning sclera
safety and effectiveness study of the herculink 14 stent to treat renal artery disease

Conditions: Renal Artery Obstruction

Summary: the purpose of this study is to evaluate the safety and effectiveness of the rx herculink 14 peripheral stent system in treating atherosclerotic renal artery stenosis.

a prospective, non-randomized, multi-center, single-arm clinical trial to evaluate the safety and efficacy of the rx herculink™ 14 peripheral stent system in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (pta) results in de novo or restenotic atherosclerotic renal artery stenoses.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of renal artery atherosclerosis; candidate for renal artery angioplasty and stenting; blood pressure \>160/90 exclusion criteria: * totally occluded renal artery on the opposite side; only one functioning kidney; target lesion is in a transplanted kidney; renal insufficiency
phase ii trial of transdermal estradiol for hormone refractory prostate cancer

Conditions: Prostate Cancer

Summary: multiple trials have shown the efficacy of estrogen therapy in metastatic prostate cancer, and most recently trials have supported the use of transdermal estrogens (patch) in the patient population with a decreased risk of cardiovascular disease as compared to the oral estrogens. we plan to study the use of transdermal estrogen at a dose of 0.4mg qd. we will evaluate the toxicities and measure quality of life. we will assess psa response and measurable disease response. this will be a trial available to the cancer institute of new jersey oncology group. we will enroll a total of 33 patients. we will plan to enroll 10 at cinj.patients will wear the patches (4) continuously. we will obtain blood work and clinic evaluations every three weeks. we will assess quality of life through a questionnaire given to patient every three weeks.


Eligibility criteria:
inclusion criteria * patients with metastatic prostate adenocarcinoma, who have failed initial hormone therapy and who have had progression after at least one chemotherapy regimen that included docetaxel. patients on antiandrogens must have progression after withdrawal of the antiandrogen for 4 weeks (flutamide) or 6 weeks (bicalutamide). * psa ≥ 10 ng/ml. * patients who have received lhrh agonist therapy for \> 1 month must maintain agonist therapy while on-study. patients who have not received agonist therapy or received \< 1 month of therapy, may not begin or continue agonist therapy while on-study. * age \>18 years and an estimated life expectancy of at least 4 months. * ecog performance status ≤ 2 (see appendix b). * full recovery from the effects of any prior surgery or radiation therapy within 4 weeks of study entry. * serum creatinine ≤ 1.5 x uln * total bilirubin \< uln * transaminases (sgot and/or sgpt) ≤ 2 x institutional upper limit. * capacity to give informed, written consent. exclusion criteria * any coexisting medical condition precluding full compliance with the study. * any history of deep venous thrombosis (dvt) or pulmonary embolus. patients with a dvt on anticoagulants for ≥ 6 months will be eligible. * known cns metastasis. * the discontinuation of flutamide or bicalutamide \< 4 or 6 weeks respectively. * history of severe cardiovascular disease (aha class iii or iv; see appendix c), uncontrolled chf or life threatening cardiac dysrhythmia in the past 6 months. * herbal supplements may not be used while on-study and patients must have discontinued use for ≥ 1 week before entering on-study. * patients with a known hypersensitivity to estrogen. * triglyceride \> 200 mg/dl. * prior estramustine.

Keywords: prostate cancer
bruxism awareness in dental students

Conditions: Bruxism

Summary: clinical students in the faculty of dentistry were diagnosed with bruxism according to the bruxism assessment consensus 2018. a total of 128 students with (64) and without (64) bruxism, were asked 33 questions about their knowledge and self-awareness about bruxism.

this study included systemically healthy individuals aged 18 to 27. intraoral and extraoral examinations were performed on 128 students with (64) and without bruxism (64), 4th and 5th-grade dental students at bolu abant i̇zzet baysal university who met the inclusion criteria. the diagnosis of bruxism was based on the 2018 international consensus and data collected through a validated 33-item questionnaire covering general information and bruxism awareness. the questionnaire included questions on bruxism's types, risk factors, symptoms, and impact on periodontal tissues, with multiple-choice responses. statistical analyses were performed using ibm spss statistics, and p\<0.05 was accepted as statistical significance

Eligibility criteria:
inclusion criteria: * systemically healthy individuals exclusion criteria: * individuals with mental retardation, * individuals with suicidal tendencies, * individuals with dementia, * individuals with psychosis

Keywords: awareness bruxism dental students questionnaire
a prospective and retrospective cohort study in patients with chronic forms of acid sphingomyelinase deficiency (asmd)

Conditions: Sphingomyelin Lipidosis

Summary: primary objective: * to describe the clinical features and their severity at the time of diagnosis and their evolution over time in patients with confirmed chronic visceral and chronic neurovisceral forms of asmd * to describe clinician-reported outcomes (clinros) and patient-reported outcomes (pros) at enrollment and their evolution over time; disease severity at the time of diagnosis and its evolution over time secondary objectives: * to describe abnormal values in laboratory parameters and all values of specific clinical and imaging assessments at the time of diagnosis and their evolution over time * to study the use and applicability towards validation of a newly developed asmd disease severity scoring system * to study the use and applicability towards validation of a newly developed asmd pro tool * to describe asmd-related disease burden among patients with asmd, caregivers, and healthcare resource utilization * to describe the association between patient demographics (eg, age, gender, race, ashkenazi ancestry) and genotype with selected clinical features in patients with confirmed chronic visceral and chronic neurovisceral forms of asmd

estimated average of study duration (for each patient) is 2 years

Eligibility criteria:
inclusion criteria : * patients with confirmed diagnosis of chronic forms of asmd based on 1) a clinical diagnosis consistent with chronic visceral asmd (ie, npd b) or chronic neurovisceral asmd (ie, npd b variant or intermediate npd a/b) and 2) deficient enzymatic activity (as measured in peripheral leukocytes, cultured fibroblasts, lymphocytes, or dbs) or presence of 2 pathogenic smpd1 mutations, * the patient (or patient's legal guardian) must provide signed informed consent. exclusion criteria: patients suspected or diagnosed with infantile onset asmd (ie, npd a, with progressive developmental delay, or presence of any combination of r498l, l304p, and p333fs\*52 genotypes, if available), * patients having received or receiving an investigational drug, * patients receiving any asmd specific ert, * patients with poor general condition that would not be able to undergo study assessments as per investigator's clinical judgment. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
177lu-lnc1011 in patients with metastatic castration-resistant prostate cancer

Conditions: Metastatic Castration-resistant Prostate Cancer

Summary: this study employed an open-label, non-randomized design, representing the first human trial of its kind. it utilized a standard 3+3 dose-escalation approach, focusing on patients with metastatic castration-resistant prostate cancer, initiating treatment at a dose of 1.85 gbq over a 6-week period. subsequent cohorts underwent sequential 50% dose escalations until the observation of dose-limiting toxicity (dlt).

\[177lu\]lu-lnc1011 is a novel long-circulating psma therapeutic probe. this study represents the first human investigation, aiming to explore its maximum tolerated dose (mtd), safety, dosimetry, and initial treatment efficacy in patients with metastatic castration-resistant prostate cancer (mcrpc).this study employed an open-label, non-randomized design, representing the first human trial of its kind. it utilized a standard 3+3 dose-escalation approach, focusing on patients with metastatic castration-resistant prostate cancer, initiating treatment at a dose of 1.85 gbq over a 6-week period. subsequent cohorts received a dose escalation of 0.925 gbq from the previous cohort.

Eligibility criteria:
inclusion criteria: * progressive metastatic castration-resistant prostate cancer * tumors with high psma expression confirmed on 68ga-psma pet/ct psma expression confirmed on 68ga-psma pet/ct exclusion criteria: * a serum creatinine level of more than 150 μmol per liter * a hemoglobin level of less than 10.0 g/dl * a white-cell count of less than 4.0× 109/l * a platelet count of less than 100 × 109/l * a total bilirubin level of more than 3 times the upper limit of the normal range * a serum albumin level of more than 3.0 g per deciliter * cardiac insufficiency

Keywords: psma 177lu mcrpc
transplantation of cultivated corneal epithelial sheet in patients with ocular surface disease

Conditions: Eye Injury

Summary: the aim of the study is to assess if transplantation of cultivated corneal epithelial stem cells could restore vision in patients with severe ocular surface disorder with a favourable safety profile that warrants further comparative study.

objectives: efficacy: to determine the efficacy of cultivated corneal epithelial stem cells as a treatment for patients with severe ocular surface disorder. the corneal limbal epithelial stem cell transplant (clet) successful outcome will be measured by improvement of vision, maintenance of corneal re-epithelisation with absence of recurrence of surface disease and subjective improvement of symptoms.

Eligibility criteria:
inclusion criteria: 1. male or non-pregnant females between 18 and 75 years of age. 2. written informed consent obtained from patient or parents/guardian. 3. patients with unilateral limbal stem deficiency 2-12 months presenting with any of the following * conjunctivalisation * absence of limbal palisades of vogts * chronic inflammation * persistent or recurrent corneal epithelial defect 4. patients who had 2-12 months of conservative treatment. \* diagnostic criteria for limbal stem cell deficiency are as follows: * symptoms of decreased vision, redness, watering, photophobia and recurrent attacks of pain * triad of signs: conjunctivalisation, neovascularisation and chronic inflammation * stippled appearance of cunjunctivalised cornea with loss of palisades of vogt * recurrent and persistent epithelial defects * superficial vascularisation, scarring, thick fibrovascular pannus, ulceration, melting and perforation exclusion criteria: patients with any of the following are not eligible for enrollment into the study: 1. pregnant or nursing woman or women of childbearing potential except if post-menopausal, surgically sterile or using accepted method(s) of birth control or having negative pregnancy test. 2. participation in any drug trial in which the patient received an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the screening phase of this study. 3. those persons directly involved in the conduct of the study. 4. any history of severe infection such as hepatitis, renal, gastrointestinal, endocrine or neurological disease. 5. evidence of corneal stromal scarring, cataract, macular oedema or scarring, retinal detachment and conjunctival keratinisation 6. positive for hiv, hepatitis b, c and vdrl 7. history of pulmonary tuberculosis, hepatitis b, 8. history of alcohol or substance abuse 9. history of malignancy within previous 5 years 10. history of organ transplant 11. any serious medical conditions or disability, which in the opinion of the investigator, would interfere with treatment or assessment or preclude completion of this study.
comparative evaluation of various combinable magnetic resonance (cmr) pulse-sequences for macrophage imaging using ferucarbotran

Conditions: Acute Myocardial Infarction

Summary: the aim of this study is to: * clarify whether macrophage imaging using ferucarbotran is able to delineate the region of myocardial infarction as accurate as gadolinium-based necrosis/fibrosis imaging; * identify possible differences in infarct imaging using ferucarbotran for macrophage imaging compared to necrosis/fibrosis imaging with gadolinium-based compounds; and * evaluate which mri pulse-sequences maximise sensitivity for macrophage imaging with ferucarbotran in the setting of acute myocardial infarction.


Eligibility criteria:
inclusion criteria: * acute myocardial infarction (stemi or nstemi) exclusion criteria: * contraindication to cmr or magnevist® or resovist®
rapid versus slow entral feeding advancements on clinical outcomes of preterm infants

Conditions: Preterm Infant

Summary: rapid versus slow entral feeding advancements on clinical outcomes of preterm infants

rapid feeding advancement achieves full enteral volume of feedings earlier than the slower advancement.they received significantly fewer days of parenteral nutrition, exhibited a shorter time to regain birth weight and shorter duration of hospital stay. the incidence of nec and the number of episodes of feeding intolerance were not significantly different between rapid and slow advancement. while the incidence of culture-proven late onset sepsis was significantly less in infants receiving a rapid feeding advancement

Eligibility criteria:
inclusion criteria: - all preterm neonates admitted to nicu with gestational age less than 36 weeks, and haemodynamically stable exclusion criteria: * gastrointestinal tract anomalies, * haemodynamically unstable infants, * gestatinal age equal or more than 36 weeks, * preterms who develop nec, * preterms on mechanical ventilation.
orchid: an online intervention for persons with hiv (miami)

Conditions: HIV/AIDS; HPV Infection

Summary: the purpose of this research is to test orchid (optimizing resilience \& coping with hiv through internet delivery), a skills-building intervention that improves mental health status for persons with hiv, who are at-risk for falling out of care.


Eligibility criteria:
inclusion criteria: 1. cis-gender women, 2. receiving human immunodeficiency virus (hiv) care at the university of miami women's hiv service, 3. recent history (12-month) of cervical or anal dysplasia or human papilloma virus (hpv) positivity; and a recent (12-month) history of one or more of the following: i) drug use (alcohol, tobacco products, marijuana, illicit drugs) or ii) depression or iii) psychiatric condition (anxiety, post-traumatic stress disorder (ptsd)) or iv) unsuppressed hiv viral load d. all life stages - pregnant, non-pregnant, pre/post-menopausal exclusion criteria: 1. under 18 2. not able to read/write english at the 6th grade level 3. cognitively impaired adults (as documented in medical records) 4. debilitating psychiatric condition (e.g. schizophrenia/bi-polar/psychotic disorders) 5. prisoners

Keywords: depression mobile applications cortisol levels
the effect of 4-7-8 breathing exercise training on sleep quality

Conditions: Nursing Students

Summary: research; it will be carried out kilis 7 aralik university yusuf serefoglu health sciences faculty, department of nursing. the training will take approximately 20 minutes in an empty classroom and will be planned when the students' classes finish. thus, educational activities in the institution will not be disrupted. participants will be asked to do the taught exercise in half an hour before going to sleep every evening during the research period (4 weeks). training will begin when the determined number of samples is reached. the training will be terminated when the 4-week research period determined to see the effect of the application expires.


Eligibility criteria:
inclusion criteria: * volunteer * studying in a nursing undergraduate program * there is no condition that prevents nasal breathing (such as septal deviation) * no known chronic sleeping disorder exclusion criteria: * no studying in a nursing undergraduate program * there is condition that prevents nasal breathing (such as septal deviation) * having any chronic sleeping disorder
mbct for psoriasis patients with anxiety and depression

Conditions: Psoriasis

Summary: this study investigates the effectiveness of a 24-week mindfulness intervention in reducing symptoms in psoriasis patients with anxiety and depression.

an adapted mbct intervention will be offered to people with psoriasis with depression and/or anxiety. 8-week long mbct therapy will be held between august 2021 and jan 2022, based on the adapted protocol. the mbct intervention will consist of 30-minute weekly groups focused on teaching mindfulness techniques and ways to recognize cognitive patterns that can increase anxiety and/or depression. participants will be recruited from the community, according to the eligibility criteria detailed below. for all participants, anxiety and/or depressive symptom severity(sas/sds), pasi,dlqi,(as measured with standardized, validated scales) will be compared baseline and weeks 2;4;8;12;16;20;24. itch intensity ,itch perception ,quality of sleep, hours missing at work ,helpfulness of common itch therapies serve as the secondary outcome, using a paired t-test.

Eligibility criteria:
inclusion criteria: * the age ranged from 18 to 70 years old * fulfilled the classification criteria for psoriasis * the score of the sds \> 50 and / or sas \>50 * participant has normal or corrected to normal vision and hearing * participant is willing and able to give informed consent for participation in the study. exclusion criteria: * participant has insufficient manual dexterity for the computerized tasks * severe systemic diseases * patients with severe mental illness or taking psychotic drugs * pregnancy * no access to the internet
to compare blephapad combo vs standard treatment for eyelid cleansing in bilateral posterior blepharitis

Conditions: Bilateral Blepharitis (Disorder)

Summary: the purpose of this study is to evaluate the efficacy of, and patient satisfaction with blephapad combo in the treatment of posterior blepharitis.

blepharitis is the most common condition in patients seeking an eye examination due to discomfort or eye irritation. treatment of blepharitis is recommended even in mild cases as chronic inflammation may cause permanent damage to the meibomian glands. each eye of each patient represents an experimental unit. each patient will apply blephapad combo to one eye and standard treatment to the other eye in accordance with the randomization procedure. the aim of this randomized, controlled study with a closed sequential design is to evaluate versus standard treatment the efficacy of, and patient satisfaction with blephapad combo in the treatment of posterior blepharitis.

Eligibility criteria:
inclusion criteria: * age \> 40 years * male or female * diagnosis of bilateral posterior blepharitis * written informed consent of patient exclusion criteria: * treatment with topical ophthalmic drugs (artificial tears allowed) * ocular surgery in the previous 6 months * pregnant or breastfeeding women * alcohol abuse * psychiatric disorders * cognitive impairment that could affect evaluation of preferences * participation in other clinical studies in the last month * hypersensitivity to one or more components of the study products